SymbolNXEN
NameNEXIEN BIOPHARMA, INC.
SectorUNDEFINED
RegionNorth America
Industry-
Address80246 United States CO 4340 East Kentucky Avenue Suite 206
Telephone(303) 495-7583
Fax
Email
Websitehttp://www.nexienbiopharma.com
IncorporationUS
Incorporated On1952
Employees
Fiscal Year6/30
Public Since
ExchangesOTC
AuditorM&K CPAS, PLLC;
Audit StatusAUDITED
Reporting StatusDark: Alternative Reporting Standard
CIK0001625288
Description

Nexien BioPharma Inc. is a US-based pharmaceutical company engaged in the formulation, development and commercialization of cannabinoid-based pharmaceuticals, in accordance with U.S. Food and Drug Administration (FDA) pre-clinical and clinical pathways, to address a broad range of medical conditions and disorders. Nexien BioPharmas drug development strategy consists of: A. The determination of medical conditions and disorders that could potentially benefit from cannabinoid-based formulations; B. Conducting "freedom to operate" investigations on these conditions; C. The preparation of patent applications and the prosecution of such application and/or the licensing of existing patents; D. Identifying the regulatory pathway with the FDA; and E. Proceeding with pre-clinical and clinical development activities in accordance with FDA protocols for submission to obtain approval for the particular product(s).

Additional info from OTC:
Nexien BioPharma Inc. is a US-based pharmaceutical company engaged in the formulation, development and commercialization of cannabinoid-based pharmaceuticals, in accordance with U.S. Food and Drug Administration (FDA) pre-clinical and clinical pathways, to address a broad range of medical conditions and disorders. Nexien BioPharmas drug development strategy consists of: A. The determination of medical conditions and disorders that could potentially benefit from cannabinoid-based formulations; B. Conducting "freedom to operate" investigations on these conditions; C. The preparation of patent applications and the prosecution of such application and/or the licensing of existing patents; D. Identifying the regulatory pathway with the FDA; and E. Proceeding with pre-clinical and clinical development activities in accordance with FDA protocols for submission to obtain approval for the particular product(s).

2025-09-19 17:17

New Form 15-12G - NEXIEN BIOPHARMA, INC. Filed: 2025-09-19 AccNo: 0001493152-25-014184 Size: 16 KB

Read more
2025-05-14 00:00

(38% Neutral) NEXIEN BIOPHARMA, INC. (NXEN) Reports 50% Loss Increase for 2025-03-31

Read more
2025-02-14 00:00

(38% Neutral) NEXIEN BIOPHARMA, INC. (NXEN) Reports 39% Loss Increase for 2024-12-31

Read more
2024-11-18 00:00

(38% Neutral) NEXIEN BIOPHARMA, INC. (NXEN) Reports 134% Loss Increase for 2024-09-30

Read more
2024-11-14 20:14

New Form NT 10-Q - NEXIEN BIOPHARMA, INC. Filed: 2024-11-14 AccNo: 0001493152-24-045731 Size: 21 KB

Read more
2024-09-30 10:07

New Form NT 10-K - NEXIEN BIOPHARMA, INC. Filed: 2024-09-30 AccNo: 0001493152-24-038663 Size: 21 KB

Read more
2024-05-28 15:59

Greenberg Richard S 🟢 acquired 6.0M shares (7 derivative) of NEXIEN BIOPHARMA, INC. (NXEN) at $0.66 Transaction Date: May 23, 2024 | Filing ID: 010007

Read more
2024-05-28 15:58

Wasoff Evan L 🟢 acquired 120.0K shares (3 derivative) of NEXIEN BIOPHARMA, INC. (NXEN) at $0.66 Transaction Date: May 23, 2024 | Filing ID: 010004

Read more